Disc Medicine Inc (IRON)
34.14
-0.52
(-1.50%)
USD |
NASDAQ |
May 29, 16:00
34.14
0.00 (0.00%)
After-Hours: 20:00
Disc Medicine Cash from Operations (TTM): -71.60M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -71.60M |
| December 31, 2023 | -73.46M |
| September 30, 2023 | -65.33M |
| June 30, 2023 | -67.55M |
| March 31, 2023 | -64.02M |
| December 31, 2022 | -42.25M |
| September 30, 2022 | -13.09M |
| Date | Value |
|---|---|
| June 30, 2022 | -19.49M |
| March 31, 2022 | -26.23M |
| December 31, 2021 | -27.53M |
| September 30, 2021 | -55.88M |
| June 30, 2021 | -46.73M |
| March 31, 2021 | -37.83M |
| December 31, 2020 | -32.71M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-73.46M
Minimum
Dec 2023
-13.09M
Maximum
Sep 2022
-45.98M
Average
-44.49M
Median
Cash from Operations (TTM) Benchmarks
| ACADIA Pharmaceuticals Inc | 63.71M |
| Alnylam Pharmaceuticals Inc | 189.12M |
| Marinus Pharmaceuticals Inc | -113.98M |
| Rocket Pharmaceuticals Inc | -194.21M |
| Regenxbio Inc | -192.94M |